The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Immutep’s experimental sarcoma therapy, a move that could streamline the drug’s development path for rare cancers. The status provides tax credits, fee waivers, and seven years of market exclusivity if approved.
Analysts note this marks the second orphan drug designation for Immutep this year, following a January approval for another rare cancer treatment. “This validates their platform’s potential in niche oncology applications,” said a biotech analyst speaking anonymously due to firm policy.
Sarcoma accounts for just 1% of adult cancers but has limited treatment options. The FDA grants about 600 orphan designations annually, with approximately 40% eventually gaining full approval. Clinical trials for the therapy are expected to begin Q4 2024.
Market observers suggest the designation could make Immutep more attractive to potential partners, though some caution that early-stage biotech investments carry significant risk. The company’s shares rose 8% in after-hours trading following the announcement.